In February 2012 Astra Zeneca received approval from the European Medicines Agency for Calpresa (Vandetanib), the first and only tyrosine kinase inhibitor licensed for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
The approval of Calpresa was based of the results of the ZETA Study, a placebo controlled clinical study of 331 patients with advanced MTC.
If you have advanced MTC, ask your Thyroid Cancer Care Team about Calpresa.
Excellence in Oncology
'Bright Ideas'
Highly Recommended
